A potential novel biomarker: comprehensive analysis of prognostic value and immune implication of CES3 in colonic adenocarcinoma

[1]  Patrick Niekamp,et al.  Microbial Metabolite Dysbiosis and Colorectal Cancer , 2023, Gut and liver.

[2]  D. Lin,et al.  Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden , 2023, JAMA network open.

[3]  Dafne Müller.  Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy , 2022, BioDrugs.

[4]  J. Daouk,et al.  NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells , 2022, Cancer Cell International.

[5]  C. Yi,et al.  Predictive biomarkers of colon cancer immunotherapy: Present and future , 2022, Frontiers in Immunology.

[6]  A. Hidalgo-Miranda,et al.  Cancer Genomics. , 2022, Archives of medical research.

[7]  Shu-wen Yu,et al.  PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages , 2022, Journal of Experimental & Clinical Cancer Research.

[8]  M. Aoki,et al.  The cAMP/PKA/CREB and TGF-β/SMAD4 pathways regulate stemness and metastatic potential in colorectal cancer cells. , 2022, Cancer research.

[9]  Yan Liang,et al.  Astragalus mongholicus Bunge and Curcuma aromatica Salisb. inhibits liver metastasis of colon cancer by regulating EMT via the CXCL8/CXCR2 axis and PI3K/AKT/mTOR signaling pathway , 2022, Chinese Medicine.

[10]  H. Wajant,et al.  TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer , 2022, Cancers.

[11]  Trevor J Pugh,et al.  Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy , 2022, Nature Immunology.

[12]  Wei Cheng,et al.  Immunotherapy: Reshape the Tumor Immune Microenvironment , 2022, Frontiers in Immunology.

[13]  Jun Wu,et al.  The Role of Lipid Metabolism in Gastric Cancer , 2022, Frontiers in Oncology.

[14]  Tao Jiang,et al.  Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. , 2022, Cancer cell.

[15]  J. Song,et al.  Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy , 2022, Frontiers in Immunology.

[16]  Jiang-jie Liu,et al.  Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma , 2022, Frontiers in Cell and Developmental Biology.

[17]  A. Kulasinghe,et al.  Immune Checkpoint Inhibitors in Cancer Therapy , 2022, Current oncology.

[18]  M. Lv,et al.  Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients , 2022, Investigational New Drugs.

[19]  Tao Yang,et al.  Untargeted metabolomics analysis of esophageal squamous cell cancer progression , 2022, Journal of translational medicine.

[20]  Junchao Luo,et al.  Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis , 2022, Frontiers in Endocrinology.

[21]  M. Althubiti,et al.  In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network , 2022, Cancers.

[22]  Wei Wei,et al.  The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma , 2022, Molecular medicine.

[23]  Jun Chen,et al.  Ferroptosis in cancer and cancer immunotherapy , 2022, Cancer communications.

[24]  P. Hao,et al.  Liquidambaric acid inhibits Wnt/β-catenin signaling and colon cancer via targeting TNF receptor-associated factor 2. , 2022, Cell reports.

[25]  Dongliang Yang,et al.  A prognostic model of non small cell lung cancer based on TCGA and ImmPort databases , 2022, Scientific reports.

[26]  Baixiao Zhao,et al.  Acupuncture for cancer pain: an evidence-based clinical practice guideline , 2022, Chinese Medicine.

[27]  Yong Zeng,et al.  Comprehensive Analysis of Immune Implication and Prognostic Value of IFI44L in Non-Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[28]  Meiwan Chen,et al.  Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy , 2021, Advanced science.

[29]  Songbing He,et al.  TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer. , 2021, Journal of gastrointestinal oncology.

[30]  M. Sotelo,et al.  Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives , 2021, Journal of clinical and translational research.

[31]  Weimin Ma,et al.  Role of NRP1 in Bladder Cancer Pathogenesis and Progression , 2021, Frontiers in Oncology.

[32]  N. Almog,et al.  Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.

[33]  Jianbo Gao,et al.  TCGA-TCIA-Based CT Radiomics Study for Noninvasively Predicting Epstein-Barr Virus Status in Gastric Cancer. , 2021, AJR. American journal of roentgenology.

[34]  Jin Jiang.  Hedgehog signaling mechanism and role in cancer. , 2021, Seminars in cancer biology.

[35]  T. Lassila,et al.  Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues , 2021, Molecular pharmaceutics.

[36]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[37]  K. Yamaguchi,et al.  Immunotherapy in Colorectal Cancer: Current and Future Strategies , 2021, Journal of the anus, rectum and colon.

[38]  M. Gerling,et al.  Hedgehog Signaling in Colorectal Cancer: All in the Stroma? , 2021, International journal of molecular sciences.

[39]  Anping Li,et al.  Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma , 2021, Cancer Immunology, Immunotherapy.

[40]  Zhimin Lu,et al.  Lipid metabolism and cancer , 2020, The Journal of experimental medicine.

[41]  J. Christensen,et al.  Cytotoxic CD8+ T cells in cancer and cancer immunotherapy , 2020, British Journal of Cancer.

[42]  J. Izbicki,et al.  TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer , 2020, Nature Communications.

[43]  E. King,et al.  NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors , 2020, Cancer Research.

[44]  M. Karin,et al.  Immunotherapy, Inflammation and Colorectal Cancer , 2020, Cells.

[45]  G. Stark,et al.  Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis , 2020, Nature Communications.

[46]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[47]  S. Zick,et al.  Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment , 2017, CA: a cancer journal for clinicians.

[48]  Qiuyang Zhang,et al.  Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. , 2017, Immunology letters.

[49]  Ahmed Kamel,et al.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[50]  M. Philip,et al.  CD8+ T cell differentiation and dysfunction in cancer , 2016, Nature Reviews Immunology.

[51]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  R. Lehner,et al.  Tumor-Induced Hyperlipidemia Contributes to Tumor Growth , 2016, Cell reports.

[53]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[54]  K. Sukhdeo,et al.  Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A , 2013, The Journal of experimental medicine.

[55]  A. Harris,et al.  How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.

[56]  F. Gonzalez,et al.  Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. , 2012, Cell metabolism.

[57]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[58]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[59]  J. VandeBerg,et al.  A new class of mammalian carboxylesterase CES6. , 2009, Comparative biochemistry and physiology. Part D, Genomics & proteomics.

[60]  Sara K Quinney,et al.  Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[61]  V. Dolinsky,et al.  The cloning and expression of a murine triacylglycerol hydrolase cDNA and the structure of its corresponding gene. , 2001, Biochimica et biophysica acta.

[62]  T. Satoh,et al.  Changes in Carboxylesterase Isoenzymes of Rat Liver Microsomes during Hepatocarcinogenesis , 1991, Japanese journal of cancer research : Gann.